27/03/2026
For tuberculosis, particularly in high-burden settings, the emphasis is often on advanced testing technologies.
Many laboratories face persistent hurdles before a specimen reaches the assay.
Issues such as inconsistent screening criteria, variable specimen quality, and incomplete clinical metadata are common.
In the latest global reporting, rifampicin resistance testing coverage among bacteriologically confirmed TB has improved, but it is still not universal.
World Health Organizationโs consolidated guidance continues to position rapid molecular tests as the initial diagnostic approach in many settings.
So the overlooked question becomes: what actually breaks the chain between a test result and transmission control?
The teams that seem to perform best treat TB diagnostics as a systems problem:
๐ญ) ๐ฃ๐ฟ๐ฒ-๐ฎ๐ป๐ฎ๐น๐๐๐ถ๐ฐ๐ฎ๐น ๐ฑ๐ถ๐๐ฐ๐ถ๐ฝ๐น๐ถ๐ป๐ฒ
Specimen quality checks and rejection criteria are used, and a fast path for recollection.
๐ฎ) ๐ฅ๐ถ๐๐ธ-๐ถ๐ป๐ณ๐ผ๐ฟ๐บ๐ฒ๐ฑ ๐ฟ๐ผ๐๐๐ถ๐ป๐ด
Clear flags for close contacts, people living with HIV, prior TB treatment, and suspected drug resistance, so the right test is run first.
๐ฏ) ๐ฅ๐ฒ๐๐ถ๐๐๐ฎ๐ป๐ฐ๐ฒ ๐ถ๐ป๐๐ฒ๐น๐น๐ถ๐ด๐ฒ๐ป๐ฐ๐ฒ
Steps to make sure possible drug resistance is checked and reported so doctors can act on it, not just stored as data.
๐ฐ) ๐ฅ๐ฒ๐ฝ๐ผ๐ฟ๐๐ถ๐ป๐ด
Results are structured to support clinicians and public health teams, including follow-up prompts when data are missing.
TB is airborne. Laboratories cannot control exposure events that already happened, but they can control whether the diagnostic pathway produces a rapid, decision-ready answer.
We support workflows with comprehensive TB diagnostic solutions, from molecular and culture-based systems to quality consumables and lab workflow support designed to enable earlier, more reliable detection.
